<DOC>
	<DOCNO>NCT00599989</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . PURPOSE : This clinical trial study side effect partial breast radiation therapy well work treat woman undergo breast conservation therapy early-stage breast cancer .</brief_summary>
	<brief_title>Partial Breast Radiation Therapy Treating Women Undergoing Breast Conservation Therapy Early-Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To allow woman undergo breast conservation therapy early-stage breast cancer access accelerate partial breast irradiation therapy control trial . - To capture prospective data acute late toxicity disease recurrence patient treat therapy . - To summarize institutional experience patient treat experimental therapy . OUTLINE : Within 9 week surgery , patient undergo accelerate partial breast irradiation ( include conformal external-beam irradiation , interstitial brachytherapy , intracavitary brachytherapy , proton beam irradiation ) twice daily 5 day ( 10 fraction ) . After completion study therapy , patient follow every 3 6 month least 5 year annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Women choose undergo breast conservation therapy , include lumpectomy breast irradiation , University Pennsylvania invasive mammary carcinoma intraductal breast cancer Stage III invasive intraductal breast cancer Unifocal tumor ≤ 3.0 cm size Patients microscopic multifocality eligible provide total pathologic tumor size ≤ 3 cm No proven multicentric carcinoma 1 quadrant separate 4 centimeter Pre postbiopsy ipsilateral* breast MRI negative multicentric disease ( i.e. , area cancer remove single excision specimen ) suspicious finding NOTE : *Patients synchronous bilateral breast cancer treat radiotherapy breast eligible , provide treatment perform manner avoids overlap treatment field . Both side may treat partial breast irradiation ( PBI ) pathologic eligibility criterion meet tumor , one side may treat PBI criterion meet one tumor . Negative margin excision ( ≥ 2 mm ) OR tumor see reexcision specimen No extensive intraductal component present Negative sentinel lymph node ( SLN ) axillary lymph node dissection OR few 4 positive node adequate axillary lymph node dissection ( i.e. , 10 lymph node remove ) If SLN positive hematoxylin eosin ( immunohistochemistry alone ) , complete axillary lymph node dissection require Axillary lymph node staging require patient ductal carcinoma situ No SLN identify internal mammary node No node &gt; 2 cm No node extracapsular extension Surgical clip place operative bed OR ability visualize operative bed CT scan breast Target lumpectomy cavity/whole breast reference volume must ≤ 30 % base treatment plan CT scan No diffuse calcification diagnostic mammogram Negative postbiopsy mammogram require present mammographically detected microcalcifications Hormone receptor status unspecified PATIENT CHARACTERISTICS : Female Menopausal status specify History nonbreast malignancy allow provided patient disease free 5 year prior randomization deem physician low risk recurrence Treated carcinoma situ cervix , carcinoma situ colon , melanoma situ , basal cell squamous cell skin cancer within past 5 year allow Patients must agree undergo breast MRI No contraindication MRI , include pacemaker foreign body Not pregnant nursing No technical impediment appropriate dosimetry No personal history collagen vascular disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior infield irradiation No presence breast implant No breast reconstructive surgery prior study entry No prior neoadjuvant chemotherapy hormonal therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>long-term effect secondary cancer therapy adult</keyword>
	<keyword>skin reaction secondary radiation therapy</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>invasive lobular breast carcinoma predominant situ component</keyword>
	<keyword>invasive lobular breast carcinoma</keyword>
	<keyword>comedo ductal breast carcinoma</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>invasive ductal breast carcinoma</keyword>
	<keyword>medullary ductal breast carcinoma lymphocytic infiltrate</keyword>
	<keyword>mucinous ductal breast carcinoma</keyword>
	<keyword>papillary ductal breast carcinoma</keyword>
	<keyword>tubular ductal breast carcinoma</keyword>
	<keyword>Paget disease breast intraductal carcinoma</keyword>
	<keyword>Paget disease breast invasive ductal carcinoma</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>